keyword
https://read.qxmd.com/read/38375659/examination-of-the-mechanisms-underlying-the-discriminative-stimulus-properties-of-the-atypical-antipsychotic-amisulpride
#1
JOURNAL ARTICLE
Timothy J Donahue, Todd M Hillhouse, Kevin A Webster, Richard Young, Eliseu O De Oliveira, Joseph H Porter
Amisulpride is an atypical benzamide antipsychotic/antidepressant, whose mechanism of action is thought to depend mainly on dopamine D2/3 receptor activity, but also with some serotonin 5-HT2B/7 effects. The present study examined the role of D2/3 receptors and 5-HT2B/7 receptors in amisulpride's discriminative stimulus. Selective agonists and antagonists of the above receptors were tested in adult, male C57BL/6 mice trained to discriminate 10 mg/kg amisulpride from vehicle in a two-lever drug discrimination assay...
February 1, 2024: Behavioural Pharmacology
https://read.qxmd.com/read/37865249/removal-of-pharmaceutical-compounds-from-the-liquid-phase-of-anaerobic-sludge-in-a-pilot-scale-high-rate-algae-bacteria-pond
#2
JOURNAL ARTICLE
Marco Mantovani, Simone Rossi, Elena Ficara, Elena Collina, Francesca Marazzi, Marina Lasagni, Valeria Mezzanotte
This study evaluates the effectiveness of a pilot-scale high-rate algae-bacteria pond (HRAP) to remove pharmaceutical compounds (PhACs) from municipal centrate. The studied PhACs belonged to different classes of synthetic active compounds: antihypertensives, antiepileptics, antidepressants, neuroprotectors, and anti-inflammatory drugs. The HRAP, growing a mixed microalgal consortium made of Chlorella spp. and Scenedesmus spp., was operated in continuous mode (6 days hydraulic retention time) from May to November 2021...
October 19, 2023: Science of the Total Environment
https://read.qxmd.com/read/37864424/a-narrative-review-of-non-racemic-amisulpride-sep-4199-for-treatment-of-depressive-symptoms-in-bipolar-disorder-and-lb-102-for-treatment-of-schizophrenia
#3
REVIEW
Jie Wu, Angela Th Kwan, Taeho Greg Rhee, Roger Ho, Giacomo d'Andrea, Giovanni Martinotti, Kayla M Teopiz, Felicia Ceban, Roger S McIntyre
INTRODUCTION: The challenges posed by treatment-resistant schizophrenia and depressive symptoms have led to ongoing difficulties despite the availability of antipsychotics and antidepressants. This review addresses the potential of amisulpride analogs, particularly SEP-4199, in addressing these challenges through enhanced efficacy and reduced side effects. AREAS COVERED: This review focuses on the pharmacological profile of amisulpride analogs, exemplified by LB-102 and its derivative SEP-4199...
October 21, 2023: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/37550314/effects-of-ulotaront-on-brain-circuits-of-reward-working-memory-and-emotion-processing-in-healthy-volunteers-with-high-or-low-schizotypy
#4
JOURNAL ARTICLE
Francesca Perini, Jadwiga Maria Nazimek, Shane Mckie, Liliana P Capitão, Jessica Scaife, Deepa Pal, Michael Browning, Gerard R Dawson, Hiroyuki Nishikawa, Una Campbell, Seth C Hopkins, Antony Loebel, Rebecca Elliott, Catherine J Harmer, Bill Deakin, Kenneth S Koblan
Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist without antagonist activity at dopamine D2 or the serotonin 5-HT2A receptors, has demonstrated efficacy in the treatment of schizophrenia. Here we report the phase 1 translational studies that profiled the effect of ulotaront on brain responses to reward, working memory, and resting state connectivity (RSC) in individuals with low or high schizotypy (LS or HS). Participants were randomized to placebo (n = 32), ulotaront (50 mg; n = 30), or the D2 receptor antagonist amisulpride (400 mg; n = 34) 2 h prior to functional magnetic resonance imaging (fMRI) of blood oxygen level-dependent (BOLD) responses to task performance...
August 7, 2023: Schizophrenia (Heidelb)
https://read.qxmd.com/read/37227597/new-pharmacologic-approaches-to-the-treatment-of-bipolar-depression
#5
REVIEW
Kamyar Keramatian, Trisha Chakrabarty, Anais DuBois, Gayatri Saraf, Lakshmi N Yatham
Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primary driver of functional impairment and suicidality in BD. Despite this, there are few effective treatments for BD depression, with only a handful of atypical anti-psychotics and inconsistent evidence for traditional mood stabilizing agents. There have been few major 'breakthroughs' in the treatment of BD depression, and until recently, few agents that work via novel mechanisms of action to exert therapeutic effects...
July 2023: Drugs
https://read.qxmd.com/read/37083542/antidepressive-effectiveness-of-amisulpride-aripiprazole-and-olanzapine-in-patients-with-schizophrenia-spectrum-disorders-a-secondary-outcome-analysis-of-a-pragmatic-randomized-trial-best-intro
#6
JOURNAL ARTICLE
Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnsen
BACKGROUND: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum...
April 22, 2023: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/36644883/apathy-associated-with-antidepressant-drugs-a-systematic-review
#7
REVIEW
Vasilios G Masdrakis, Manolis Markianos, David S Baldwin
OBJECTIVES: Administration of antidepressant drugs - principally selective serotonin reuptake inhibitors (SSRIs) - may induce clinically significant 'apathy' which can affect treatment outcomes adversely. We aimed to review all relevant previous reports. METHODS: We performed a PUBMED search of English-language studies, combining terms concerning psychopathology (e.g. apathy) and classes of antidepressants (e.g. SSRI). RESULTS: According to certain inclusion (e...
August 2023: Acta Neuropsychiatrica
https://read.qxmd.com/read/35615528/rechallenge-with-amisulpride-in-a-patient-with-schizophrenia-following-a-manic-episode-during-previous-therapy
#8
Li-Yu Hu, Chen-Jee Hong, Shih-Jen Tsai, Cheng-Che Shen
Amisulpride is an atypical antipsychotic. It is also effective in treating depression. The potential antidepressant effect raises the concern that amisulpride can induce mania. However, reports of amisulpride-induced mania have been rare. Here, we present the case of a Taiwanese woman with a 22-year history of schizophrenia. At the age 57 years, she developed manic symptoms while on treatment with amisulpride for six weeks. She was immediately admitted to the psychiatric in-patient unit. The manic symptoms completely subsided within eight days without the administration of any mood stabilizer...
2022: Case Reports in Psychiatry
https://read.qxmd.com/read/34614447/a-randomized-double-blind-placebo-controlled-proof-of-concept-trial-to-evaluate-the-efficacy-and-safety-of-non-racemic-amisulpride-sep-4199-for-the-treatment-of-bipolar-i-depression
#9
JOURNAL ARTICLE
Antony Loebel, Kenneth S Koblan, Joyce Tsai, Ling Deng, Maurizio Fava, Justine Kent, Seth C Hopkins
BACKGROUND: Non-racemic amisulpride (SEP-4199) is an 85:15 ratio of aramisulpride:esamisulpride with a 5-HT7 and D2 receptor binding profile optimized for the treatment of bipolar depression. The aim of this study was to evaluate the efficacy and safety of SEP-4199 for the treatment of bipolar depression. METHODS: Patients meeting DSM-5 criteria for bipolar I depression were randomized to 6 weeks of double-blind, placebo-controlled treatment with SEP-4199 200 mg/d or 400 mg/d...
October 3, 2021: Journal of Affective Disorders
https://read.qxmd.com/read/34530775/transitory-restless-arms-syndrome-in-a-patient-with-antipsychotics-and-antidepressants-a-case-report
#10
JOURNAL ARTICLE
Juan Chen, Na Meng, Bingrong Cao, Yinghua Ye, Ying Ou, Zhe Li
BACKGROUND: Restless arms syndrome (RAS) is characterized by uncomfortable aching or burning sensations in the arms. RAS is regarded as an upper limb variant of restless legs syndrome (RLS). The lack of specific diagnostic criteria makes it difficult to recognize the RAS. Therefore, RAS is usually neglected in clinical practice. Moreover, when a patient was diagnosed with RAS, the adjustment of medications was the first choice for doctors, which may make the patient's condition unstable...
September 16, 2021: BMC Psychiatry
https://read.qxmd.com/read/34365490/false-positive-drug-test-results-in-patients-taking-psychotropic-drugs-a-literature-review
#11
REVIEW
Sebastian Masternak, Olga Padała, Hanna Karakuła-Juchnowicz
INTRODUCTION: The study reviews the literature on false-positive drug test results in patients taking psychotropic medications. METHOD: A narrative review of available literature in English and Polish was conducted by searching MEDLINE/PubMed and Google Scholar databases using the search phrase ‛falsepositive drug test' and names of selected registered antidepressant, antipsychotic and mood stabilizing medications as well as pharmaceuticals used in the treatment of ADHD...
April 30, 2021: Psychiatria Polska
https://read.qxmd.com/read/34281223/transcriptional-modulation-of-the-hippo-signaling-pathway-by-drugs-used-to-treat-bipolar-disorder-and-schizophrenia
#12
JOURNAL ARTICLE
Bruna Panizzutti, Chiara C Bortolasci, Briana Spolding, Srisaiyini Kidnapillai, Timothy Connor, Mark F Richardson, Trang T T Truong, Zoe S J Liu, Gerwyn Morris, Laura Gray, Jee Hyun Kim, Olivia M Dean, Michael Berk, Ken Walder
Recent reports suggest a link between positive regulation of the Hippo pathway with bipolar disorder (BD), and the Hippo pathway is known to interact with multiple other signaling pathways previously associated with BD and other psychiatric disorders. In this study, neuronal-like NT2 cells were treated with amisulpride (10 µM), aripiprazole (0.1 µM), clozapine (10 µM), lamotrigine (50 µM), lithium (2.5 mM), quetiapine (50 µM), risperidone (0.1 µM), valproate (0.5 mM), or vehicle control for 24 h. Genome-wide mRNA expression was quantified and analyzed using gene set enrichment analysis (GSEA), with genes belonging to Hippo, Wnt, Notch, TGF- β, and Hedgehog retrieved from the KEGG database...
July 2, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/33961287/discovery-of-nonracemic-amisulpride-to-maximize-benefit-risk-of-5-ht7-and-d2-receptor-antagonism-for-the-treatment-of-mood-disorders
#13
JOURNAL ARTICLE
Seth C Hopkins, Scott Wilkinson, Taryn J Corriveau, Hiroyuki Nishikawa, Keiko Nakamichi, Antony Loebel, Kenneth S Koblan
In contrast to the dose-occupancy relationship in the treatment of schizophrenia, the minimal effective level of dopamine receptor 2 (D2R) blockade for antipsychotics in the treatment of bipolar depression is unknown. Lower doses aimed at reducing extrapyramidal side effects must be balanced against the need to retain the therapeutic benefit of D2R blockade on emergent cycling, mixed, manic, anxiety, and/or psychotic symptoms. Dose-reductions intended to lower D2R blockade, however, could also decrease concomitant serotonin receptor antagonism and its potential benefit on depressive symptoms...
September 2021: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/33566440/worsening-of-myasthenia-due-to-antiepileptic-antipsychotic-antidepressant-and-sedative-medication-an-estimation-of-risk-based-on-reporting-frequency
#14
JOURNAL ARTICLE
Peter Trillenberg, Alexander Katalinic, Klaus Junghanns, Julia Thern
BACKGROUND AND PURPOSE: Many drugs can worsen myasthenia symptoms. The clinician usually relies on cautionary lists compiled according to case reports. We intended to provide a quantitative basis for a risk comparison within the groups of antiepileptic, antidepressant, neuroleptic, and sedative drugs. METHODS: We extracted adverse drug reaction (ADR) counts (total and myasthenia related) for drugs from these groups and calculated the reporting odds ratio (ROR) within the drug groups from the World Health Organization pharmacovigilance database...
July 2021: European Journal of Neurology
https://read.qxmd.com/read/33230596/arrhythmias-related-to-antipsychotics-and-antidepressants-an-analysis-of-the-summaries-of-product-characteristics-of-original-products-approved-in-germany
#15
JOURNAL ARTICLE
Mohamed Elsayed, Emaad Abdel-Kahaar, Maximilian Gahr, Bernhard J Connemann, Michael Denkinger, Carlos Schönfeldt-Lecuona
PURPOSE: Most psychiatric drugs, such as antidepressants (AD) and antipsychotics (AP), may cause cardiac adverse events (CAE). We used summaries of product characteristics (SmPC) for assessing the likelihood of AD and AP to cause CAE. METHODS: We identified all original medicinal products (OMP) of AD and AP approved in Germany. We searched for their SmPCs using the online services of PharmaNet.Bund, Gelbe liste®, Rote Liste®, Fachinfo-Service®, and via manufacturer contact...
May 2021: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/32800810/amisulpride-alleviates-chronic-mild-stress-induced-cognitive-deficits-role-of-prefrontal-cortex-microglia-and-wnt-%C3%AE-catenin-pathway
#16
JOURNAL ARTICLE
Ahmed M Mohamed, Mohamed Z Habib, Mai A Ebeid, Sahar M Abdelraouf, Yasser El Faramawy, Sawsan Aboul-Fotouh, Yosra Magdy
Accumulating evidence indicates the role of microglial activation and sustained neuroinflammation in the pathogenesis of cognitive dysfunction, a common feature associated with depressive disorders. It also indicates the role of Wnt/β-catenin pathway in regulation of microglia-mediated neuroinflammation. Amisulpride exhibits antidepressant and pro-cognitive activities in several clinical and experimental studies. Hitherto, the direct effects of amisulpride on Wnt/β-catenin signaling and microglial activity have not been thoroughly studied...
August 12, 2020: European Journal of Pharmacology
https://read.qxmd.com/read/32421188/clozapine-combination-and-augmentation-strategies-in-patients-with-schizophrenia-recommendations-from-an-international-expert-survey-among-the-treatment-response-and-resistance-in-psychosis-trrip-working-group
#17
JOURNAL ARTICLE
Elias Wagner, John M Kane, Christoph U Correll, Oliver Howes, Dan Siskind, William G Honer, Jimmy Lee, Peter Falkai, Thomas Schneider-Axmann, Alkomiet Hasan
BACKGROUND: Evidence for the management of inadequate clinical response to clozapine in treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was undertaken with the aim of developing consensus recommendations for treatment strategies for clozapine-refractory patients with schizophrenia. METHODS: We conducted an online survey among members of the Treatment Response and Resistance in Psychosis (TRRIP) working group. An agreement threshold of ≥75% (responses "agree" + "strongly agree") was set to define a first-round consensus...
December 1, 2020: Schizophrenia Bulletin
https://read.qxmd.com/read/31875650/segmental-analysis-of-antidepressant-and-antipsychotic-drugs-in-the-hair-of-schizophrenic-patients
#18
JOURNAL ARTICLE
Xin Wang, Yue Zhuo, Xiaowei Tang, Huosheng Qiang, Wei Liu, Hejian Wu, Ping Xiang, Gengli Duan, Min Shen
Hair analysis is useful for documenting long-term exposure to drugs. The potential of hair analysis for therapeutic drug monitoring within the forensic field has been studied, but reference values for some antidepressants and antipsychotics in the hair of individuals undergoing chronic therapy are still lacking. In the present study, a method was developed and validated for the determination of 23 analytes, including antidepressants, antipsychotics and related metabolites, in human hair by liquid chromatography-tandem mass spectrometry (LC-MS/MS)...
December 25, 2019: Drug Testing and Analysis
https://read.qxmd.com/read/31784354/machine-learning-identifies-large-scale-reward-related-activity-modulated-by-dopaminergic-enhancement-in-major-depression
#19
JOURNAL ARTICLE
Yuelu Liu, Roee Admon, Monika S Mellem, Emily L Belleau, Roselinde H Kaiser, Rachel Clegg, Miranda Beltzer, Franziska Goer, Gordana Vitaliano, Parvez Ahammad, Diego A Pizzagalli
BACKGROUND: Theoretical models have emphasized systems-level abnormalities in major depressive disorder (MDD). For unbiased yet rigorous evaluations of pathophysiological mechanisms underlying MDD, it is critically important to develop data-driven approaches that harness whole-brain data to classify MDD and evaluate possible normalizing effects of targeted interventions. Here, using an experimental therapeutics approach coupled with machine learning, we investigated the effect of a pharmacological challenge aiming to enhance dopaminergic signaling on whole-brain response to reward-related stimuli in MDD...
October 22, 2019: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://read.qxmd.com/read/31291218/amisulpride-as-an-augmentation-agent-in-treatment-resistant-depression-a-case-series-and-review-of-the-literature
#20
REVIEW
Hans Rittmannsberger
Amisulpride (AMS) in low dosage has been used effectively for treatment of dysthymia. Yet there is a dearth of reports on its use as an augmentation agent in therapy-resistant depression. We deal with this issue presenting case reports and a review of the literature. The addition of 50 mg amisulpride (AMS) to antidepressant therapy in seven patients with depression at different stages of treatment resistance, one of them a case of recurrent brief depression, is described in this report. Augmentation with AMS led to a profound improvement in psychopathology in most patients...
June 2019: Psychiatria Danubina
keyword
keyword
70446
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.